ISSN 1671-5411 CN 11-5329/R
Volume 18 Issue 10
Oct.  2021
Turn off MathJax
Article Contents
Please cite this article as: Bazoukis G, Papadatos SS, Thomopoulos C, Tse G, Cheilidis S, Tsioufis K, Farmakis D. Impact of SGLT2 inhibitors on major clinical events and safety outcomes in heart failure patients: a meta-analysis of randomized clinical trials. J Geriatr Cardiol 2021; 18(10): 783−795. DOI: 10.11909/j.issn.1671-5411.2021.10.003
Citation: Please cite this article as: Bazoukis G, Papadatos SS, Thomopoulos C, Tse G, Cheilidis S, Tsioufis K, Farmakis D. Impact of SGLT2 inhibitors on major clinical events and safety outcomes in heart failure patients: a meta-analysis of randomized clinical trials. J Geriatr Cardiol 2021; 18(10): 783−795. DOI: 10.11909/j.issn.1671-5411.2021.10.003

Impact of SGLT2 inhibitors on major clinical events and safety outcomes in heart failure patients: a meta-analysis of randomized clinical trials

doi: 10.11909/j.issn.1671-5411.2021.10.003
More Information
  •  BACKGROUND Sodium-glucose co-transporter-2 inhibitors (SGLT2i) significantly reduce the risk of cardiovascular (CV) and renal adverse events in patients with diabetes mellitus, heart failure (HF) and/or chronic kidney disease. We performed a meta-analysis to explore the impact of several different SGLT2i on all-cause mortality, CV mortality, HF hospitalizations and the combined outcome CV death/HF hospitalization in HF patients across the spectrum of left ventricular ejection fraction (LVEF) phenotypes. METHODS A systematic search in MEDLINE database and Cochrane library through March 2021 was performed without limitations. Randomized clinical trials that provided data about the impact of SGLT2i on all-cause mortality, CV mortality, HF hospitalizations or the combined outcome of CV death/HF hospitalization in HF patients were included. A random effects model was used for calculating the effect estimates. RESULTS Nine studies (n = 16,723 patients, mean age: 65.9 years, males: 70.7%) were included in the quantitative synthesis. Compared to placebo, SGLT2i use was associated with 14% lower risk of all-cause mortality [hazard ratio (HR) = 0.86, 95% CI: 0.78−0.94, I2 = 0, P = 0.0008], 32% lower risk of HF hospitalizations (HR = 0.68, 95% CI: 0.62−0.74, I2 = 0, P < 0.001), 14% lower risk of CV mortality (HR = 0.86, 95% CI: 0.77−0.95, I2 = 0, P = 0.003) and 26% lower risk of CV death/HF hospitalization (HR = 0.74, 95% CI: 0.68−0.80, I2 = 0, P < 0.001). Regarding the safety outcomes, our data revealed no significant differences between SGLT2i and placebo groups in drug related discontinuations, amputations, severe hypoglycemia, hypotension, volume depletion, ketoacidosis and genital infections. By contrast, a protective role of SGLT2i against placebo was found for serious adverse events and acute kidney injury. CONCLUSIONS In patients with HF, regardless of LVEF phenotype, all SGLT2i had an excellent safety profile and significantly reduced the risk of all-cause mortality, CV mortality, HF hospitalizations and CV deaths/HF hospitalizations compared to placebo.
  • loading
  • [1]
    Kalra S. Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology. Diabetes Ther 2014; 5: 355−366. doi: 10.1007/s13300-014-0089-4
    [2]
    Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117−2128. doi: 10.1056/NEJMoa1504720
    [3]
    Neal B, Perkovic V, Matthews DR, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 2099. doi: 10.1056/NEJMc1712572
    [4]
    Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347−357. doi: 10.1056/NEJMoa1812389
    [5]
    Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380: 2295−2306. doi: 10.1056/NEJMoa1811744
    [6]
    Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383: 1436−1446. doi: 10.1056/NEJMoa2024816
    [7]
    Cherney DZI, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2017; 5: 610−621. doi: 10.1016/S2213-8587(17)30182-1
    [8]
    McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381: 1995−2008. doi: 10.1056/NEJMoa1911303
    [9]
    Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41: 255−323. doi: 10.1093/eurheartj/ehz486
    [10]
    Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 2020; 396: 819−829. doi: 10.1016/S0140-6736(20)31824-9
    [11]
    Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383: 1413−1424. doi: 10.1056/NEJMoa2022190
    [12]
    Writing Committee, Maddox TM, Januzzi JL Jr, et al. 2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2021; 77: 772−810. doi: 10.1016/j.jacc.2020.11.022
    [13]
    Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097. doi: 10.1371/journal.pmed.1000097
    [14]
    Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, et al. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 2006; 11: 193−206. doi: 10.1037/1082-989X.11.2.193
    [15]
    Fellow J, Altman DG. Assessing Risk of Bias in Included Studies, Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series. A John Wiley & Sons, Ltd., Publication: the Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England, 2008: 187–241.
    [16]
    Rådholm K, Figtree G, Perkovic V, et al. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS Program. Circulation 2018; 138: 458−468. doi: 10.1161/CIRCULATIONAHA.118.034222
    [17]
    Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J 2016; 37: 1526−1534. doi: 10.1093/eurheartj/ehv728
    [18]
    Cosentino F, Cannon CP, Cherney DZI, et al. Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial. Circulation 2020; 142: 2205−2215. doi: 10.1161/CIRCULATIONAHA.120.050255
    [19]
    Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 2021; 384: 117−128. doi: 10.1056/NEJMoa2030183
    [20]
    Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 2019; 139: 2528−2536. doi: 10.1161/CIRCULATIONAHA.119.040130
    [21]
    Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation 2019; 140: 1463−1476. doi: 10.1161/CIRCULATIONAHA.119.042929
    [22]
    Sarraju A, Li J, Cannon CP, et al. Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: results from the CREDENCE trial. Am Heart J 2021; 233: 141−148. doi: 10.1016/j.ahj.2020.12.008
    [23]
    Kosiborod M, Lam CSP, Kohsaka S, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J Am Coll Cardiol 2018; 71: 2628−2639. doi: 10.1016/j.jacc.2018.03.009
    [24]
    Li D, Liu Y, Hidru TH, et al. Protective effects of sodium-glucose transporter 2 inhibitors on atrial fibrillation and atrial flutter: a systematic review and meta- analysis of randomized placebo-controlled trials. Front Endocrinol (Lausanne) 2021; 12: 619586. doi: 10.3389/fendo.2021.619586
    [25]
    Kumar K, Kheiri B, Simpson TF, et al. Sodium-glucose cotransporter-2 inhibitors in heart failure: a meta-analysis of randomized clinical trials. Am J Med 2020; 133: e625−e630. doi: 10.1016/j.amjmed.2020.04.006
    [26]
    Chambergo-Michilot D, Tauma-Arrué A, Loli-Guevara S. Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: a systematic review and meta-analysis. Int J Cardiol Heart Vasc 2020; 32: 100690. doi: 10.1016/j.ijcha.2020.100690
    [27]
    Li X, Zhang Q, Zhu L, et al. Effects of SGLT2 inhibitors on cardiovascular, renal, and major safety outcomes in heart failure: a meta-analysis of randomized controlled trials. Int J Cardiol 2021; 332: 119−126. doi: 10.1016/j.ijcard.2021.03.077
    [28]
    Damman K, Beusekamp JC, Boorsma EM, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail 2020; 22: 713−722. doi: 10.1002/ejhf.1713
    [29]
    Anker SD, Butler J, Filippatos G, et al. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. Eur J Heart Fail 2020; 22: 2383−2392. doi: 10.1002/ejhf.2064
    [30]
    McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol 2021; 6: 148−158. doi: 10.1001/jamacardio.2020.4511
    [31]
    Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci 2020; 5: 632−644. doi: 10.1016/j.jacbts.2020.02.004
    [32]
    Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 2021; 77: 243−255. doi: 10.1016/j.jacc.2020.11.008
    [33]
    Farmakis D, Butler J, Filippatos G. Sodium-glucose co-transporter 2 inhibitors: ‘a tale of two sisters’, diabetes and heart failure. Eur J Heart Fail 2020; 22: 1259−1262. doi: 10.1002/ejhf.1935
    [34]
    Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323−334. doi: 10.1056/NEJMoa1515920
    [35]
    Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2019; 7: 845−854. doi: 10.1016/S2213-8587(19)30256-6
    [36]
    Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393: 31−39. doi: 10.1016/S0140-6736(18)32590-X
    [37]
    Menne J, Dumann E, Haller H, et al. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis. PLoS Med 2019; 16: e1002983. doi: 10.1371/journal.pmed.1002983
    [38]
    Mordi NA, Mordi IR, Singh JS, et al. Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: the RECEDE-CHF trial. Circulation 2020; 142: 1713−1724. doi: 10.1161/CIRCULATIONAHA.120.048739
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(20)  / Tables(1)

    Article Metrics

    Article views (118) PDF downloads(9) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return